Medipal Holdings Corporation · TSE:7459
Medipal — Q1 FY2026 Earnings Presentation
19 slides from Medipal's earnings presentation, Aug 5, 2026
Slide 1: Financial Results for the First Quarter Ended June 30, 2026
August 5, 2026 Financial Results for the First Quarter Ended June 30, 2026 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” an Orchestra in Support of People's Health The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being and to e
Slide 2: Contents
Contents Revision of Full-Year Consolidated Earnings and Dividend Forecasts 1 for the Fiscal Year Ending March 31, 2027 (Announced on July 14, 2026) Financial Results for the First Quarter Ended 2 June 30, 2026 The MEDIPAL Group has three business segments: Regarding the description of the business
Slide 3: Revision of Full-Year Consolidated Financial Forecasts and Dividend Forecast
Revision of Full-Year Consolidated Financial Forecasts and Dividend Forecast for the Fiscal Year Ending March 31, 2027 (Announced on July 14, 2026) Completed the tender offer for shares of PALTAC CORPORATION on July 7, 2026 Scheduled to complete making PALTAC a wholly owned subsidiary via squeez
Slide 4: Revision of Full-Year Consolidated Financial Forecasts for FY2026
Revision of Full-Year Consolidated Financial Forecasts for FY2026 (Announced on July 14, 2026) Positive Impact on Net Profit from Incorporating PALTAC’s Non-Controlling Interests ¥ : billion Previous Forecast Revised Forecast (Announced on May 14, 2026) (Announced on July 14, 2026) Forecast (% of Ne
Slide 5: Revision of Dividend Forecast for FY2026
Revision of Dividend Forecast for FY2026 (Announced on July 14, 2026) Significantly revised dividend forecasts upward to enhance shareholder returns, in light of future financial conditions Nearly All of the ¥4.0 Billion Net Profit Gain from PALTAC Integration Dedicated to Dividend Increases (yen) D
Slide 6: Contents
Contents Revision of Full-Year Consolidated Earnings and Dividend Forecasts 1 for the Fiscal Year Ending March 31, 2027 (Announced on July 14, 2026) Financial Results for the First Quarter Ended 2 June 30, 2026 The MEDIPAL Group has three business segments: Regarding the description of the business
Slide 7: Overview of Financial Results for 1Q/FY2026
Overview of Financial Results for 1Q/FY2026 Achieved revenue growth across all business segments. Although operating profit decreased slightly, net profit grew significantly Net sales exceeded the same period of the previous year across all business segments, driving a +4.7% YoY increase in consol
Slide 8: 1Q/FY2026 Consolidated Results
1Q/FY2026 Consolidated Results Amount YoY Change Change factors from 1Q/FY2025 Net Sales ¥989.5 billion ＋¥44.3 billion [+4.7%] Net sales increased across all segments Operating Gross Profit ： +¥1.0 billion Profit ¥13.3 billion ¥(0.6 billion) [(4.7%)] SG＆A expenses ： +¥1.7 billion • PALTAC Business :
Slide 9: 1Q/FY2026 MEDICEO Business
1Q/FY2026 MEDICEO Business Achieved sales growth outperforming market growth, driven by increased demand for products covered by the Innovative New Drug Price Maintenance System* and sales expansion in hospital and dispensing pharmacy channels Steadily secured gross profit growth, while SG&A expense
Slide 10: 1Q/FY2026 PALTAC Business
1Q/FY2026 PALTAC Business Net sales grew. Operating profit declined due to an increase in SG&A expenses Net sales increased as the expansion of newly handled products and sales promotion measures capturing consumer purchasing behavior were successful Amount YoY Change Change factors from 1Q/FY2025
Slide 11: 1Q/FY2026 AGRO & FOOD Business
1Q/FY2026 AGRO & FOOD Business New consolidation of Cygni Corporation drove growth in net sales and operating profit Promoting integration with Cygni Corporation, leveraging its strong e-commerce capabilities to expand sales in the companion animal market Amount YoY Change Change factors from 1Q/FY2
Slide 12: Appendix
Appendix Copyright © 2026 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 12
Slide 13: 1Q/FY2026 Consolidated Statements
1Q/FY2026 Consolidated Statements ¥:billion 1Q/FY2025 1Q/FY2026 Results Results YoY [% of Net Sales] [% of Net Sales] YoY Change % of Change Net Sales 945.1 989.5 +44.3 +4.7% Gross Profit 64.6 65.7 +1.0 +1.6% [6.84％] [6.64％] [(0.20pp)] SG&A Expenses 50.6 52.3 +1.7 +3.4% [5.36%] [5.29％] [(0.07pp)] SG
Slide 14: Factors behind YoY changes in Gross Profit, Operating Profit, and Ordinary Profit
Factors behind YoY changes in Gross Profit, Operating Profit, and Ordinary Profit MEDICEO business +0.4 （¥ billion） PALTAC business SG＆A expenses（Increase） Non-Operating (0.1) Income/Expenses (1.7) AGRO＆FOOD +0.3 business +0.7 +1.0 Decrease in MEDICEO business +0.3 Increase in Increase in non-operat
Slide 15: Factors behind YoY changes in Ordinary Profit to Profit attributable to Owners of Parent
Factors behind YoY changes in Ordinary Profit ,Profit before Income Taxes, and Profit attributable to Owners of Parent Extraordinary Income/Expenses （¥ billion） +5.3 Gain on sale of Business Total investment Insurance Loss on restructuring income Profit attributable securities claim income valuation
Slide 16: 1Q/FY2026 MEDICEO Business
1Q/FY2026 MEDICEO Business ¥:billion 1Q/FY2025 1Q/FY2026 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 600.0 630.5 +30.5 +5.1% Gross Profit 36.7 37.2 +0.4 +1.2% [6.13%] [5.91%] [(0.23pp)] SG&A Expenses 31.2 30.9 (0.3) (1.0%) [5.21%] [4.91%] [(0.30pp)] SG&A Ex
Slide 17: 1Q/FY2026 PALTAC Business
1Q/FY2026 PALTAC Business ¥:billion 1Q/FY2025 1Q/FY2026 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales ３１６.０ 326.9 +10.8 +3.4% Gross ２３.６ 23.5 (0.1) (0.８%) Profit [7.49%] [7.19%] [(0.31pp)] SG&A １６.０ 17.3 +1.3 +８.１% Expenses [5.０８%] [5.３1%] [＋0.23pp] Operating
Slide 18: 1Q/FY2026 AGRO&FOOD Business
1Q/FY2026 AGRO&FOOD Business ¥:billion 1Q/FY2025 1Q/FY2026 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales ３０.１ 33.0 +2.9 +9.9％ Gross Profit ４.２ 5.0 +0.7 +18.7% (14.０２%) (15.13%) (+1.11pp) SG&A Expenses ３.４ 3.9 +0.4 +14.0% (11.４７%) (11.89%) (+0.42pp) SG&A Expen
Slide 19: Forward-Looking Statements
【Forward-Looking Statements】 These materials reflect analysis of available information and various trends as of the date on the cover. Risks and uncertainties affecting the Company’s business could cause actual results to differ materially from any projections presented in these materials. In the ev